

| | | | |
|---|--|----------------------------|--------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | SERIAL NO. | 10/587,823 |
| | | FILING DATE | December 20, 2006 |
| | | APPLICANT | Mercep et al. |
| | | GROUP | 1624 |
| | | EXAMINER | N.E. Jarrell |
| | | ATTORNEY DOCKET NO. | PLP537USW |

U.S. PATENT DOCUMENTS

| Examiner Initials | | Patent Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
|-------------------|---|---------------|---------------|-------------------|-------|----------|-------------------------------|
| | 1 | 3,711,489 | Jan. 16, 1973 | Lombardino | | | |
| | 2 | 3,894,032 | July 8, 1975 | Remy | | | |
| | 3 | 3,974,285 | Aug. 10, 1976 | Remy | | | |
| | 4 | 4,044,143 | Aug. 23, 1977 | Remy | | | |
| | 5 | 4,198,421 | Apr. 15, 1980 | Cherkofsky et al. | | | |
| | 6 | 5,917,057 | June 29, 1999 | Hamer et al. | | | |
| | | | | | | | |

Continue on page

FOREIGN PATENT DOCUMENTS

| | | Document Number | Publication Date | Country | Class | Subclass | Translation Yes No |
|--|----|-----------------|------------------|---------|-------|----------|-------------------------|
| | 7 | CA 967,573 | May 13, 1975 | CANADA | | | |
| | 8 | WO 97/38991 | Oct. 23, 1997 | WIPO | | | |
| | 9 | WO 99/00355 | Jan. 7, 1999 | WIPO | | | |
| | 10 | WO 01/87890 | Nov. 22, 2001 | WIPO | | | |
| | 11 | WO 03/097649 | Nov. 27, 2003 | WIPO | | | |
| | 12 | WO 03/099823 | Dec. 4, 2003 | WIPO | | | |
| | 13 | HR 20000310 | Feb. 28, 2002 | CROATIA | | | X |
| | 14 | HR 20020453 | May 23, 2002 | CROATIA | | | X |
| | | | | | | | |
| | | | | | | | |

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

| | | |
|--|----|--|
| | 15 | Ackermann L., Harvima I.T. "Mast cells of psoriatic and atopic dermatitis skin are positive for TNF- α and their degranulation is associated with expression of ICAM-1 in the epidermis." Arch. Dermatol. Res. 1998, 290:353-359. |
| | 16 | Aderka, D. "Role of tumor necrosis factor in the pathogenesis of intravascular coagulopathy of sepsis: potential new therapeutic implications." Isr. J. Med. Sci., 1991, 27:52-60. |
| | 17 | Arrieta O, et al. "Protective effect of pentoxifylline plus thalidomide against septic shock in mice." Int. J. Exp. Pathol. 1999, 80(1):11-16. |
| | 18 | Badger A.M. et al. "Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock." Circ. Shock 1994 44(4):188-195. |
| | 19 | Badger et al. "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function." J. Pharmac. Env. Therap., 1996, 279(3):1453-1461. |
| | 20 | Becker et al. "Photochemistry of the Anthracene Chromophore: Novel Isomerization of 1-(9-Anthry)-2-Benzoethylenes." Tetrahedron Lett., 1985. 26(12):1589-1592. |
| | 21 | Bissonnette E. Y. et al. "Inhibition of tumour necrosis factor-alpha (TNF-alpha) release from mast cells by the anti-inflammatory drugs, sodium cromoglycate and nedocromil sodium." Clin. Exp. Immunol. 1995, 102:78-84. |
| | 22 | Bresnihan. "Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in rheumatoid arthritis (RA); results of randomized double-blind, placebo-controlled multicenter trial." Arthritis. Rheum., 1996, 39:73. |
| | 23 | Cagniant, C.R. Hebd. Sceances Acad. Sci., 1976, 283:683-686 |
| | 24 | Carswell et al. "An endotoxin-induced serum factor that causes necrosis of tumors." Proc. Natl. Acad. Sci. U.S.A., 1975, 72:3666-3670. |
| | 25 | Chapman P.T. et al. "Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1." Arthritis Rheum., 1997, 40:955-965. |

| | | |
|--|----|--|
| | 26 | Cheung A. T. et al. "An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha." <i>Endocrinology</i> , 1998, 139:4928-4935. |
| | 27 | Collier et al. "The abdominal constriction response and its suppression by analgesic drugs in the mouse." <i>Br. J. Pharmac. Chemother.</i> , 1968, 32:295-310 |
| | 28 | Corral L., et al. "Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That are Potent Inhibitors of TNF- α ." <i>The Journal of Immunology</i> 1999, 163:380-386. |
| | 29 | Dibbs Z, et al. "Cytokines in heart failure: pathogenetic mechanisms and potential treatment." <i>Proc. Assoc. Am. Physicians</i> , 1999, 111:423-428. |
| | 30 | Di Francia M. et al. "Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease." <i>AM. J. Respir. Crit. Care Med.</i> 1994, 150:1453-1455. |
| | 31 | Dinarello. "An update on human interleukin-1: From molecular biology to clinical relevance." <i>J. Clinical Immunology</i> , 1985, 5:287. |
| | 32 | Dinarello. "Interleukin-1." <i>Rev. Infect. Disease</i> , 1984, 6(1):51-95. |
| | 33 | Duong D.J. et al. "American experience with lowdose thalidomide therapy for severe cutaneous lupus erythematosus." <i>Arch. Dermatol.</i> 1999 135 (9):1079-1087. |
| | 34 | Egidio J. et al. "Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases." <i>Kidney Int. Suppl.</i> 1993, 39:59-64. |
| | 35 | Elliott et al. "Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis." <i>The Lancet</i> , 1994, 344:1105-1110. |
| | 36 | M. Feldman et al. "Role of Cytokines in Rheumatoid Arthritis." <i>Annu. Rev. Immunol.</i> 1996 14:397-440. |
| | 37 | Fukawa et al. "A method for evaluating analgesic agents in rats." <i>J. Pharmacol. Meth.</i> , 1980, 4:251-259. |
| | 38 | Gauldie J. et al. "Cytokines and pulmonary fibrosis." <i>Thorax</i> , 1993, 48:931-935. |
| | 39 | Georgopoulos et al. "Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice." <i>J. Inflamm.</i> , 1996, 46:86-97. |
| | 40 | Gruschwitz, M., et al. "In situ Expression and Serum Levels of Tumor Necrosis Factor- α Receptors in Patients with Early Stages of Systemic Sclerosis." <i>Journal Rheumatology</i> 1997; 24:1936-43. |
| | 41 | Heilig, B. et al. "Elevated TNF Receptor Plasma Concentrations in Patients with Rheumatoid Arthritis." <i>Clinical Investigation</i> 1992; 70:22-27. |
| | 42 | Heilig B et al. "[Expression of TNF receptors in rheumatoid arthritis and ankylosing spondylitis]." [Article in German]. <i>Z Rheumatol.</i> 1993 Nov-Dec; 52(6):383-9. |
| | 43 | Hotamisligil G.S., Spiegelman B.M. "Tumor necrosis factor alpha: a key component of the obesity-diabetes link." <i>Diabetes</i> , 1994, 43:1271-1278. |
| | 44 | Iyer and Gopalachari. "Studies in Potential Antifertility Agents: Part VII - Synthesis of Dialkylaminoethyl Derivatives of 2,4,5Triphenylpyrroles & 2,4,5Triphenylfurans." <i>Indian J. Chem.</i> , 1973, 11:1260-1262. |
| | 45 | Jones et al. "Antiestrogens. 2. Structure-activity studies in a series of 3-aryl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity." <i>J. Med. Chem.</i> ., 1984, 27:1057-1066. |
| | 46 | Kapadia S. et al. "The role of cytokines in the failing human heart." <i>Cardiol. Clin.</i> , 1998, 16:645-656. |
| | 47 | King, F.D. "Bioisosteres, Conformational Restriction, and Pro-Drugs – Case History: An Example of a Conformational Restriction Approach." <i>Med. Chem.: Principle and Practice</i> (1994) p. 206-208. |
| | 48 | Kefer, et al. "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis." <i>EMBO J.</i> , 1991, 10:4025-4031. |
| | 49 | Kluth D.C., Rees A.J. "Inhibiting inflammatory cytokines." <i>Semin. Nephrol.</i> 1996, 16:576-582. |
| | 50 | Kopicova et al. "Potential Tetracyclic Neuroleptics: 12-(4-methylpiperazino)benzo[b]naphtho[2,3-f]thiepin and its 12,13-dihydro Derivative." <i>Collect. Czech. Chem. Commun.</i> , 1975.40:1960-1965. |
| | 51 | Kopicova and Protiva. "Synthesis of 7-(4-methylpiperazino)-7,8-dihydrobenzo[b]naphtho[2,1-f]thiepin and of Related Compounds." <i>Collect. Czech. Chem. Commun.</i> , 1974. 39:3147-3152. |
| | 52 | Krakauer T, Stiles BG. "Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release." <i>Clin Diagn Lab Immunol.</i> 1999 Jul;6(4):594-8. |
| | 53 | Liedtke W. "Effective Treatment of Models of Multiple Sclerosis by Matrix Metalloproteinase Inhibitors." <i>An. of Neurology</i> , 1998, Vol. 44; 35-46. |
| | 54 | Liu J.Y. et al. "TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers." <i>Am. J. Pathol.</i> , 1998, 153:1839-1847. |
| | 55 | Maini R.N, Taylor P.C. "Anti-Cytokine Therapy for Rheumatoid Arthritis." <i>Annu. Rev. Med.</i> 2000 51:207-229. |
| | 56 | Martel-Pelletier J., Alaeddine N. Pelletier JP. "Cytokines and their role in the pathophysiology of osteoarthritis." <i>Front Biosci.</i> 1999 4:D694-703. |
| | 57 | Mattioli and Ghia. "Omega-dialkylaminoalkyl ethers of phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with analgesic and anti-inflammatory activity." <i>J. Heterocyclic Chem.</i> , 1997, 34:963-968. |

| | | |
|--|----|---|
| | 58 | Matsukawa A, et al. "Analysis of the Cytokine Network Among Tumor Necrosis Factor α , Interleukin-1 β , Interleukin-8 and Interleukin-I Receptor Antagonist in Monosodium Urate Crystal-Induced Rabbit Arthritis." <i>Lab Invest</i> 1998; 78:559-569. |
| | 59 | McHugh et al. "Preparation of 8H-Furo[3,4-d]dibenz[b,f]azepine. A Novel Heterocyclic Ring System." <i>J. Heterocycl. Chem.</i> , 1990, 27:1839-42. |
| | 60 | Mori et al. "Photochemical reactions of anthracene-naphthalene bichromophoric systems linked by a three-carbon chain." <i>J. Chem. Soc., Perkin Trans. 2</i> , 1996, 1:113-119. |
| | 61 | Mori et al. "Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice." <i>J. Immunol.</i> , 1996, 157:3178-3182. |
| | 62 | Noguchi, M., et al. "Secretion Imbalance between Tumor Necrosis Factor and its inhibitor in inflammatory bowel disease." <i>Gut</i> 1998, 43:203-209. |
| | 63 | Nyiondi-Bonguen et al. "[4+2] - Cycloadditions of 3-Amino-4-imino-4H-thieno[3,4-c][1]benzopyran with some Selected Dienophiles." <i>J. Chem Soc., Perkin Trans. 1</i> , 1994, 15:2191-2195. |
| | 64 | Odeh M. "Role of Cytokines in Rheumatoid Arthritis." <i>Drugs News Perspect.</i> II(6) 1998, 331-341. |
| | 65 | Oliver S., et al. "The Effect of Thalidomide and 2 Analogs on Collagen Induced Arthritis." <i>Journal of Rheumatology</i> 1998; 25:964-9. |
| | 66 | Peleman R.A., Kips J.C., Pauwels R.A. "Therapeutic activities of theophylline in chronic obstructive pulmonary disease." <i>Clin. Exp. Allergy</i> 1998 28 Supp 1. 3:53-56. |
| | 67 | Pfeffer et al. "Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to <i>L. monocytogenes</i> infection." <i>Cell</i> , 1993, 73:457-467. |
| | 68 | Piguet P.F. et al. "Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis." <i>Am. J. Pathol.</i> 1993, 143:651-655. |
| | 69 | Piguet P.F., Vesin C. "Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice." <i>Eur. Respir. J.</i> , 1994, 7:515-518. |
| | 70 | Reimund J. "In vitro effects of oxpentifylline on Inflammatory Cytokine Release in Patients with Inflammatory Bowel Disease." <i>Gut</i> 1997, 40:475-480. |
| | 71 | Ross S., et al. "Suppression of TNF α Expression, Inhibition of TH1 Activity and Amelioration of Collagen-Induced Arthritis by Rolipram." <i>Journal of Immunology</i> , 1997, 159:6253-6259. |
| | 72 | Rutgeerts P. et al. "Efficacy and Safety of Retreatment with Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease." <i>Gastroenterology.</i> , 1999, 117:761-769. |
| | 73 | Sandborn W. and Hanauer S. "Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease; A review of Agents, Pharmacology, Clinical Results and Safety." <i>Inflammatory Bowel Diseases</i> 1999, 5(2):119-133. |
| | 74 | Saricaoglu H. et al. "Prevention of nickel-induced allergic contact reactions with pentoxyfylline." <i>Contact Dermatitis</i> 1998, 39(5):244-247. |
| | 75 | Sasayama S. et al. "New insights into the pathophysiological role for cytokines in heart failure." <i>Cardiovasc Res.</i> 1999, 42:557-564. |
| | 76 | Schmidt H. et al. "Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats." <i>J. Surg. Res.</i> 1996 63(1):143-146. |
| | 77 | Schweizer et al. "Combined automated writhing/motility test for testing analgesics." <i>Agents and Actions</i> , 1988, 23:29-31. |
| | 78 | Shire, MG and Muller GW. "TNF- α inhibitors and rheumatoid arthritis." <i>Exp. Opin. Ther. Patents.</i> 1998 8(5): 531-544. |
| | 79 | Stirling D. I. Semin. "Thalidomide and its impact in dermatology." <i>Cutan. Med. Surg.</i> 1998 17(4):231-242. |
| | 80 | Sykes A.P.. et al. "The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a Erinitrobenzenesulphonic acid rat model of inflammatory bowel disease." <i>Aliment Pharmacol Ther.</i> 1999, 13:1535-1542. |
| | 81 | Taylor R. Multiple Sclerosis: A Rehabilitative Approach, 1998, 9, 3, 525-536. "Immunologic Aspects of Multiple Sclerosis." |
| | 82 | Tochtermann et al. Ein neuer Zugang zu chiralen Tribenzocycloheptarien-(Tribenzo-[a.c.e]cyclohepten-) und Tribenzo[b.d.flthiepin-S.S-dioxid-Derivaten." . <i>Chem. Ber.</i> , 1968, 101:3122-3137. |
| | 83 | Tomizawa S. et al. "TNF inhibitory activity in the urine of chronic renal failure patients with glomerulonephritis." <i>Nephron.</i> 1993, 63:111-112. |
| | 84 | Tsuji et al. "Studies on Anti-Inflammatory Agents. VI. Synthesis and Pharmacological Properties of 2,3-Diarylthiophenes." <i>Chem. Pharm. Bull.</i> , 1998, 46(2):279-286. |
| | 85 | Ueda et al. "The Synthesis of 10-(4-Methylpiperazine)dibenzo[b,flthiepin and Related Compounds. Neurotrpic and Psychotropic Agents." <i>Chem. Pharm. Bull.</i> , 1975, 23(10):2223-2231. |
| | 86 | Van Assche and Rutgeerts. "Anti-TNF agents in Crohn's disease." <i>Exp. Opin. Invest. Drugs</i> , 2000, 9:103-111. |
| | 87 | Vippagunta, S.R. et al. "Crystalline solids." <i>Advanced Drug Delivery Reviews</i> , 2001, 48(1):3-26. |
| | 88 | Wermuth et al. "Molecular Variations Based on Isosteric Replacements." <i>Practice of Medicinal Chemistry</i> , 1996, pages 203-237. |
| | 89 | Westacott C.I. et al. "Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis." <i>Osteoarthritis Cartilage</i> 2000 8(3):213-221. |

| | | |
|----------|----|---|
| | 90 | Wim B van den Berg, Ph.D. "Anti-Cytokine Therapy in Chronic Destructive Arthritis." Arthritis Res 2001, 3:18-26. |
| | 91 | Postmarketing Adverse Event Data for TNF-alpha Antagonists (October 23, 2001). Stephen A. Paget, MD < http://rheumatology.hss.edu/phys/specialreports/pagetttnf.asp > |
| | 92 | Green (Using TNF alpha technology to treat rheumatoid arthritis) Article (July/August 2004). < http://rheumatology.hss.edu/phys/specialreports/pagetttnf.asp > |
| | 93 | Centocor products (08/11/2004) < http://www.centocor.com/cgi-bin/site/products/prod_remicade.cgi > is cited for the statement that> |
| | 94 | "News & Notices: http://www.psoriasis.org/enbrel.approval.jan02.htm (7/30/2002). Continue on page _____ |
| EXAMINER | | DATE CONSIDERED |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.